An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 5700 participants.
Also called NCT07517263
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,700 participants
- Sponsor
- Registry
-
NCT07517263
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Iceland, India, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07517263. Allocation not applicable; no masking; primary purpose treatment. Start 2026-05-11 (actual); primary completion 2030-01-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Condition
- Cardiovascular Disease and Lipoprotein(a)
- Intervention (Drug)
- Pelacarsen (TQJ230)
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07517263- Content hash
eb2bc18dcc794e68100dcba772b8b2cde75faf39e62cf993b25ed693dac87915